MC10029 / Mayo Clinic - LARVOL DELTA

From gene to bedside: Mayo Clinic's first-in-house BAFF-R CAR-T (AACR 2026) - "This study represents Mayo Clinic's first homegrown CAR-T cell therapy, developed entirely in-house—from antibody discovery and CAR design to GMP manufacturing and clinical trial—marking a significant step toward personalized, next-generation immunotherapy for B-cell malignancies."

CAR T-Cell Therapy • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology

A new sort of cells for chimeric antigen receptor T-cell therapies-isolating CD14-CD127+ T cells for chimeric antigen receptor T-cell manufacture. (PubMed, Cytotherapy) - "We developed a new two-step isolation method for enriching CD14-CD127+ T cells from PBMCs. This method effectively excluded unwanted B cells, yet maintained the naïve, stem-like central memory and central memory T cells that can produce functional CAR T-cells."

Journal • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor • CD14 • FOXP3 • IL2RA • IL7R

Innovative Applications of CAR T-Cell Therapy in Organ Transplant Patients (ASGCT 2024) - "The remaining three patients with insufficient B cells, demonstrated CAR T-cells killing activity against antigen-expressing cell line models. This proof-of-concept paves the way for the first-ever application of CAR T-cell therapy in sensitized patients that await life-saving organ transplants."

CAR T-Cell Therapy • Clinical • IO biomarker • Immunology • Transplant Rejection • Transplantation

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Mayo Clinic | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Mayo Clinic | Initiation date: Jan 2024 ➔ Jun 2024

CAR T-Cell Therapy • Trial initiation date • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma